#ETRA

Electra Therapeutics Targets $342M IPO to Advance Lead Drug Ipsoprubart

Electra Therapeutics seeks a $342 million Nasdaq listing to fuel Phase III trials for its lead hyperinflammatory syndrome treatment, ipsoprubart, following strong…

Electra Therapeutics Targets $977.6 Million Valuation in Nasdaq IPO

Electra Therapeutics seeks a $977.6 million valuation as it joins a rebounding biotech IPO market, with plans to list on the Nasdaq…